Calcium Folinate

• Non inferiority study of preoperative chemotherapy without pelvic irradiation for rectal cancer Recruiting
  2024-510580-28-00 Phase III 1 country Assistance Publique Hopitaux De Paris
• Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (petosemtamab) as single agent or in combination in advanced solid … Recruiting
  2024-513627-16-01 Phase I (FiH) 5 countries Merus B.V.
• Nordic Pancreatic Cancer Trial (NORPACT) – 1 Recruiting
  2024-517719-65-00 Phase II 2 countries Oslo University Hospital HF
• A Phase 3 Study of Front‑line Platinum Doublet Therapy With Sotorasib Versus Pembrolizumab in PD-L1 Negative KRAS p.G12C Positive Advanced/M… Ended
  2022-501863-41-00 Phase III 17 countries Amgen Inc.
• A phase 3 clinical trial of a new combination treatment, domvanalimab and zimberelimab, plus chemotherapy, for people with an upper gastroin… Ended
  2023-507522-16-00 Phase III 9 countries Arcus Biosciences Inc.
• A safety and efficacy study of treatment combinations with and without chemotherapy in adult patients with advanced upper gastrointestinal t… Ended
  2024-511917-40-00 Phase II 1 country Arcus Biosciences Inc.
• ShorTrip study - Phase II study of Short-course radiotherapy followed by consolidation chemotherapy with the Triplet FOLFOXIRI as total neoa… Ended
  2024-513297-21-00 Phase II 1 country Fondazione GONO G.I.
• A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRA… Ended
  2023-506241-30-00 Phase III 15 countries Mirati Therapeutics Inc.
• Lutetium (177Lu) Edotreotide versus Best Standard of Care in Well-differentiated Aggressive Grade 2 and Grade 3 Gastroenteropancreatic Neuro… Ended
  2024-510812-64-00 Phase III 5 countries ITM Solucin GmbH
• An open-label phase 1b/2 study assessing the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic… Ended
  2024-514905-79-00 Phase I/II 3 countries Alligator Bioscience AB
• A study of patients with colorectal cancer that have a genetic abnormality in the BRAF gene taking encorafenib plus cetuximab with or withou… Ended
  2023-509405-77-00 Phase III 13 countries Pfizer Inc.
• Methotrexate and Metformin in rheumatoid arthritis patients. Ended
  2024-511033-35-00 Phase II 1 country Centre Hospitalier Universitaire De Bordeaux
• A Phase I open label followed by a Phase II randomized, controlled study to assess the efficacy and safety of ABTL0812 in combination with F… Ended
  2024-515379-36-00 Phase I/II 2 countries Ability Pharmaceuticals S.A.
• Tocotrienol and bevacizumab in metastatic colorectal cancer. A randomized phase II marker trial Ended
  2024-517075-21-00 Phase II 1 country Lillebaelt Hospital
• Irinotecan-based triplet (FOLFOXIRI) as perioperative treatment in resectable gastric and gastroesophageal junction adenocarcinoma - a phase… Ended
  2023-509044-96-00 Phase II 2 countries Region Skane
• Phase II study evaluating Holmium-166 TARE followed by maIntenance Therapy in liver limited unresectable colorectal cancer patients after fi… Ended
  2023-505356-22-00 Phase II 1 country Gruppo Oncologico Del Nord Ovest
• A Phase 2a Multicenter, Randomized, Double Blind, Parallel, Proof of concept Study Evaluating the Efficacy and Safety of Nipocalimab and Cer… Ended
  2023-504045-31-00 Phase II 3 countries Janssen - Cilag International
• Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Adv… Ended
  2022-501465-40-00 Phase II 1 country Leap Therapeutics Inc.
• This is a phase 2, randomized, double blind, multicenter study evaluating the efficacy and safety of the combination of methotrexate plus UV… Ended
  2024-512766-34-00 Phase II 1 country Centre Hospitalier Universitaire De Bordeaux
• The effect of oral folinic acid to prevent pemetrexed induced adverse events. Ended
  2022-502345-10-00 Phase IV 1 country Amphia Hospital
• SURVIVAL ANALYSIS AFTER NEOADJUVANT TREATMENT IN RESECTABLE PANCREATIC CANCER WITH RISK FACTORS Ended
  2024-519633-35-00 Phase IV 1 country La Fundacion Para La Gestion De La Investigacion Biomedica De Cadiz
• A Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer Ended
  2024-511158-36-00 Phase I/II 3 countries Arcus Biosciences Inc.
• Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Ga… Ended
  2023-504834-23-00 Phase III/IV 7 countries Merck Sharp & Dohme LLC
• RACE-trial: Neoadjuvant Radiochemotherapy versus Chemotherapy for Patients with Locally Advanced, Potentially Resectable Adenocarcinoma of t… Ended
  2024-516271-32-00 Phase III 1 country Universitat Heidelberg

Showing 49–72 of 76 trials